Epidiolex generics — when can they launch?
Epidiolex (CANNABIDIOL) · Jazz Pharms Res · 32 active US patents · 0 expired
Where Epidiolex sits in the generic timeline
Long-dated protection: earliest active US patent for Epidiolex extends to 2035 (~9 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 31 patents
- Formulation — 1 patent
FDA U-codes carved out by Epidiolex patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2421 | (no description) |
U-2443 | (no description) |
U-2454 | (no description) |
U-2427 | (no description) |
U-3375 | (no description) |
U-2780 | (no description) |
U-3235 | (no description) |
U-2781 | (no description) |
U-2425 | (no description) |
U-3988 | (no description) |
U-2862 | (no description) |
U-2424 | (no description) |
U-2426 | (no description) |
U-2422 | (no description) |
U-3071 | (no description) |
U-3072 | (no description) |
U-3233 | (no description) |
Sample patent estate
Showing 6 of 32 active US patents. View full estate on the Epidiolex drug page →
-
This patent protects the use of cannabidiol (CBD) for reducing total convulsive seizure frequency in treatment-resistant epilepsy, including Dravet syndrome and other conditions.USPTO title: Use of cannabinoids in the treatment of epilepsy
-
This patent protects the use of cannabidiol (CBD) for treating atonic seizures in patients with certain epilepsy syndromes.USPTO title: Use of cannabinoids in the treatment of epilepsy
-
This patent protects the use of cannabidiol (CBD) for treating atonic seizures in patients with certain epilepsy syndromes.USPTO title: Use of cannabinoids in the treatment of epilepsy
-
This patent protects the use of cannabidiol (CBD) for treating atonic seizures in patients with certain epilepsy syndromes.USPTO title: Use of cannabinoids in the treatment of epilepsy
-
This patent protects the use of cannabidiol (CBD) in treating absence seizures in patients with certain epilepsy-related conditions.USPTO title: Use of cannabinoids in the treatment of epilepsy
-
This patent protects the use of cannabidiol (CBD) for treating atonic seizures in patients with certain epilepsy syndromes.USPTO title: Use of cannabinoids in the treatment of epilepsy
Sources
- FDA Orange Book — patents listed against Epidiolex (NDA filed 2018)
- Epidiolex drug profile — full patent estate, indications, clinical trials, pricing
- Jazz Pharms Res patent portfolio
- Patent cliff 2035 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Epidiolex — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →